InvestorsHub Logo
Followers 25
Posts 2345
Boards Moderated 0
Alias Born 06/20/2020

Re: 10nisman post# 29004

Friday, 05/07/2021 3:24:12 PM

Friday, May 07, 2021 3:24:12 PM

Post# of 42977

So promising GILD walked away.


Humanigen walked away. And it is promising. The trial showed that lenzilumab is effective with Gilead's Yescarta but now lenz will now be trialed in combination with every CAR-T treatment that is commercially available. If it is effective with multiple CAR-T therapies, which is likely since all of their toxicity issues stem from GM-CSF, the buyout price will be astronomical. Lenzilumab might literally make CAR-T viable.